Exploiting the phenotypic states of cancer to identify new avenues of diagnosis and treatment
Launched in February of 2022
Licensed technology from The UT Southwestern Medical Center
Located in the heart of North Texas Bio Community at Pegasus Park, Dallas
Bryan Presley - President
Digant Dave', PhD - Science Advisor
Robert Bachoo, MD, PhD - Science Advisor
Elizibeth Maher, MD, PhD - Science Advisor
Azam Anwar, MD - Chairman
SingleCell Biotechnology has developed a new platform of assays to target highly aggressive and invasive cancers. The platform consists of three phenotype assays that recapitulate dormancy, migration, and single cell clonogenicity of tumor stem cells. These stem cells make up the hallmark characteristics of aggressive and highly invasive cancers responsible for recurrence and mortality. Each assay is designed to collect high content and high throughput data necessary for drug discovery and disease analysis. The platform can be used for screening drug libraries and identifying druggable targets for killing or disrupting dormant and migrating cells to expedite and de-risk the drug development process.
The SingleCell Bio platform uses proprietary protocols and 3D spatial confinement of single cells in massive arrays that allow downstream cell retrieval for multi-omic profiling. By combining high-content imaging with molecular analysis, our platform can be used to construct a phenotype-to-genotype map of each individual patient's cancer that can be used in predictive technologies and disease progression.
SingleCell Biotechnology awarded CPRIT Grant to optimize and advance its assays for use in drug development against Glioblastoma (GBM) brain tumors.
SingleCell Biotechnology successfully tests platform with primary patient agnostic GBM samples.
SingleCell Biotechnology successfully tests platform devices with GBM and Breast Cancer patient derived cell lines.
3060 Pegasus Park Dr., Dallas, TX 75247
The Biotech Hub of Dallas
Pegasus Park - Biotech Hub